Compare TENX & FRMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | FRMM |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 75.7M |
| IPO Year | 2001 | 2017 |
| Metric | TENX | FRMM |
|---|---|---|
| Price | $2.13 | $5.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $29.67 | $5.00 |
| AVG Volume (30 Days) | ★ 9.0M | 170.2K |
| Earning Date | 05-15-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,547,000.00 |
| Revenue This Year | N/A | $183.55 |
| Revenue Next Year | N/A | $166.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $1.76 |
| 52 Week High | $19.40 | $7.15 |
| Indicator | TENX | FRMM |
|---|---|---|
| Relative Strength Index (RSI) | 23.92 | 49.06 |
| Support Level | $1.31 | $5.38 |
| Resistance Level | $14.15 | $5.84 |
| Average True Range (ATR) | 0.20 | 0.42 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 75.00 | 44.14 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.